The Safety and Tolerability of 5-Aminolevulinic Acid Phosphate with Sodium Ferrous Citrate in Patients with Type 2 Diabetes Mellitus in Bahrain

Feryal Al-Saber, Waleed Aldosari, Mariam Alselaiti, Hesham Khalfan, Ahmed Kaladari, Ghulam Khan, George Harb, Riyadh Rehani, Sizuka Kudo, Aya Koda, Tohru Tanaka, Motowo Nakajima, Abdulla Darwish, Feryal Al-Saber, Waleed Aldosari, Mariam Alselaiti, Hesham Khalfan, Ahmed Kaladari, Ghulam Khan, George Harb, Riyadh Rehani, Sizuka Kudo, Aya Koda, Tohru Tanaka, Motowo Nakajima, Abdulla Darwish

Abstract

Type 2 diabetes mellitus is prevalent especially in Gulf countries and poses serious long-term risks to patients. A multifaceted treatment approach can include nutritional supplements with antioxidant properties such as 5-aminolevulinic acid (5-ALA) with sodium ferrous citrate (SFC). This prospective, randomized, single-blind, placebo-controlled, dose escalating pilot clinical trial assessed the safety of 5-ALA with SFC at doses up to 200 mg 5-ALA/229.42 mg SFC per day in patients living in Bahrain with type 2 diabetes mellitus that was uncontrolled despite the use of one or more antidiabetic drugs. Fifty-three patients (n = 53) from 3 sites at one center were enrolled by Dr. Feryal (Site #01), Dr. Hesham (Site #02), and Dr. Waleed (Site #03) (n = 35, 5-ALA-SFC; n = 18, placebo). There was no significant difference in incidence of adverse events reported, and the most frequent events reported were gastrointestinal in nature, consistent with the known safety profile of 5-ALA in patients with diabetes. No significant changes in laboratory values and no difference in hypoglycemia between patients receiving 5-ALA and placebo were noted. Overall, the current results support that use of 5-ALA-SFC up to 200 mg per day taken as 2 divided doses is safe in patients taking concomitant oral antidiabetic medications and may offer benefits in the diabetic population. This trial is registered with ClinicalTrials.gov NCT02481141.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Figure 1
Figure 1
Patient disposition. ∗includes noncompliance with dosing and inability to return for visits due to work and lack of transportation.
Figure 2
Figure 2
Cumulative adverse events reported at each visit.
Figure 3
Figure 3
Changes in mean HbA1c during dosing period ((a) ITT population, (b) PP population).

References

    1. International Diabetes Foundation. Bahrain: Diabetes in Bahrain, .
    1. World Health Organization (WHO) Global status report on noncommunicable diseases 2014.
    1. Gariballa S., Kosanovic M., Yasin J., El Essa A. Oxidative damage and inflammation in obese diabetic emirati subjects. Nutrients. 2014;6(11):4872–4880. doi: 10.3390/nu6114872.
    1. Davì G., Santilli F., Patrono C. Nutraceuticals in diabetes and metabolic syndrome. Cardiovascular Therapeutics. 2010;28(4):216–226. doi: 10.1111/j.1755-5922.2010.00179.x.
    1. Inzucchi S. E., Bergenstal R. M., Buse J. B., et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetologia. 2012;55(6):1577–1596. doi: 10.1007/s00125-012-2534-0.
    1. Zabłocka-Słowińska K., Dzielska E., Gryszkin I., Grajeta H. Dietary supplementation during diabetes therapy and the potential risk of interactions. Advances in Clinical and Experimental Medicine. 2014;23(6):939–946. doi: 10.17219/acem/37348.
    1. Yamashita N., Watanabe N., Kondo H., Kawata S., Tanaka T., Nakajima M. Safety test of a supplement, 5-aminolevulinic acid phosphate with sodium ferrous citrate, in diabetic patients treated with oral hypoglycemic agents. Functional Foods in Health and Disease. 2014;4(9):415–428.
    1. Patti M.-E., Corvera S. The role of mitochondria in the pathogenesis of type 2 diabetes. Endocrine Reviews. 2010;31(3):364–395. doi: 10.1210/er.2009-0027.
    1. Rodriguez B. L., Curb J. D., Davis J., et al. Use of the dietary supplement 5-aminiolevulinic acid (5-ALA) and its relationship with glucose levels and hemoglobin A1C among individuals with prediabetes. Clinical and Translational Science. 2012;5(4):314–320. doi: 10.1111/j.1752-8062.2012.00421.x.
    1. Higashikawa F., Noda M., Awaya T., Tanaka T., Sugiyama M. 5-Aminolevulinic acid, a precursor of heme, reduces both fasting and postprandial glucose levels in mildly hyperglycemic subjects. Nutrition. 2013;29(7-8):1030–1036. doi: 10.1016/j.nut.2013.02.008.
    1. Maruyama K., Hagiya Y., Sugiyama Y., et al. The effect of 5-aminolevulinic acid on cytochrome c oxidase activity in mouse liver. BMC Research Notes. 2011;4, article 66
    1. Patel D. N., Low W.-L., Tan L. L., et al. Adverse events associated with the use of complementary medicine and health supplements: an analysis of reports in the Singapore Pharmacovigilance database from 1998 to 2009. Clinical Toxicology. 2012;50(6):481–489. doi: 10.3109/15563650.2012.700402.
    1. Kuehn B. M. Dietary supplement linked to cases of acute hepatitis. JAMA-Journal of the American Medical Association. 2013;310(17):p. 1784. doi: 10.1001/jama.2013.281868.
    1. Bunchorntavakul C., Reddy K. R. Review article: herbal and dietary supplement hepatotoxicity. Alimentary Pharmacology and Therapeutics. 2013;37(1):3–17. doi: 10.1111/apt.12109.
    1. Guerrero-Romero F., Rodríguez-Morán M. Complementary therapies for diabetes: the case for chromium, magnesium, and antioxidants. Archives of Medical Research. 2005;36(3):250–257. doi: 10.1016/j.arcmed.2005.01.004.
    1. Nishio Y., Fujino M., Zhao M., et al. 5-Aminolevulinic acid combined with ferrous iron enhances the expression of heme oxygenase-1. International Immunopharmacology. 2014;19(2):300–307. doi: 10.1016/j.intimp.2014.02.003.
    1. Sacks D. B., Arnold M., Bakris G. L., et al. Position statement executive summary: guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes Care. 2011;34(6):1419–1423. doi: 10.2337/dc11-9997.
    1. American Diabetes Association (ADA) Standards of medical care—2015. Diabetes Care. 2015;38(1)
    1. Alahmad G., Al-Jumah M., Dierickx K. Review of national research ethics regulations and guidelines in Middle Eastern Arab countries. BMC Medical Ethics. 2012;13(1, article 34) doi: 10.1186/1472-6939-13-34.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する